

World Journal of *Gastroenterology*

World J Gastroenterol 2019 August 7; 25(29): 3838-4042





EDITORIAL

- 3838** Healthy axis: Towards an integrated view of the gut-brain health
Boem F, Amedei A
- 3842** Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we
Tsoufas G

OPINION REVIEW

- 3849** Improving cirrhosis care: The potential for telemedicine and mobile health technologies
Stotts MJ, Grischkan JA, Khungar V
- 3857** Lumen-apposing metal stents for malignant biliary obstruction: Is this the ultimate horizon of our experience?
Anderloni A, Troncone E, Fugazza A, Cappello A, Blanco GDV, Monteleone G, Repici A

REVIEW

- 3870** Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, D'Andrea M, Toffoli G
- 3897** Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions
Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S

MINIREVIEWS

- 3920** Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Tintelnot J, Stein A
- 3929** Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer H, Shibolet O, Deutsch L

ORIGINAL ARTICLE

Basic Study

- 3941** Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns
Jiraviriyakul A, Songjang W, Kaewthet P, Tanawatkitichai P, Bayan P, Pongcharoen S

- 3956** Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats

Yu ZC, Cen YX, Wu BH, Wei C, Xiong F, Li DF, Liu TT, Luo MH, Guo LL, Li YX, Wang LS, Wang JY, Yao J

- 3972** LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer

Wang W, Xie Y, Chen F, Liu X, Zhong LL, Wang HQ, Li QC

Retrospective Cohort Study

- 3985** Liquid biopsy for non-invasive assessment of liver injury in hepatitis B patients

Xia WY, Gao L, Dai EH, Chen D, Xie EF, Yang L, Zhang SC, Zhang BF, Xu J, Pan SY

Retrospective Study

- 3996** Additional laparoscopic gastrectomy after noncurative endoscopic submucosal dissection for early gastric cancer: A single-center experience

Tian YT, Ma FH, Wang GQ, Zhang YM, Dou LZ, Xie YB, Zhong YX, Chen YT, Xu Q, Zhao DB

Observational Study

- 4007** Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer

Bouché O, Ben Abdelghani M, Labourey JL, Tribby S, Bensadoun RJ, Jouary T, Des Guetz G

SYSTEMATIC REVIEW

- 4019** Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment

Pekgöz M

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Herwig Cerwenka, MD, Professor, Department of Surgery, Medical University of Graz, Graz A-8036, Austria

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. The *WJG* Editorial Board consists of 701 experts in gastroenterology and hepatology from 58 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, etc. The *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

The *WJG* is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2019 edition of Journal Citation Report® cites the 2018 impact factor for *WJG* as 3.411 (5-year impact factor: 3.579), ranking *WJG* as 35th among 84 journals in gastroenterology and hepatology (quartile in category Q2). CiteScore (2018): 3.43.

RESPONSIBLE EDITORS FOR THIS ISSUE

Responsible Electronic Editor: *Yu-Jie Ma*

Proofing Production Department Director: *Yun-Xiaoqian Wu*

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Subrata Ghosh, Andrzej S. Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Ze-Mao Gong, Director

PUBLICATION DATE

August 7, 2019

COPYRIGHT

© 2019 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Retrospective Study

Additional laparoscopic gastrectomy after noncurative endoscopic submucosal dissection for early gastric cancer: A single-center experience

Yan-Tao Tian, Fu-Hai Ma, Gui-Qi Wang, Yue-Ming Zhang, Li-Zhou Dou, Yi-Bin Xie, Yu-Xin Zhong, Ying-Tai Chen, Quan Xu, Dong-Bing Zhao

ORCID number: Yan-Tao Tian (0000-0001-6479-7547); Fu-Hai Ma (0000-0003-2437-6881); Gui-Qi Wang (0000-0001-7767-1564); Yue-Ming Zhang (0000-0002-8406-5877); Dou-Li Zhou (0000-0003-1455-4701); Yi-Bin Xie (0000-0002-7887-1389); Yu-Xin Zhong (0000-0002-8865-3297); Ying-Tai Chen (0000-0003-4980-6315); Quan Xu (0000-0001-9246-3253); Dong-Bing Zhao (0000-0001-8339-687X).

Author contributions: Tian YT and Ma FH contributed equally to this work and they were involved in study concept, data acquisition, analysis, and interpretation, and production of tables, wrote the first draft, and revised it critically in light of comments from other authors; Zhao DB was involved in study conception and design, data interpretation, manuscript revision, and discussion; Wang GQ, Zhang YM, Dou LZ, and Xu Q were involved in data acquisition and literature review; Xie YB, Zhong YX, and Chen YT were involved in the manuscript revision and discussion; all authors approved the final version submitted.

Supported by the National Natural Science Foundation of China, No. 81772642; Beijing Municipal Science and Technology Commission, No. Z16110000116045; and Capital's Funds for Health Improvement and Research, No. CFH 2018-2-4022.

Yan-Tao Tian, Fu-Hai Ma, Yi-Bin Xie, Yu-Xin Zhong, Ying-Tai Chen, Quan Xu, Dong-Bing Zhao, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Gui-Qi Wang, Yue-Ming Zhang, Li-Zhou Dou, Department of Endoscopy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Corresponding author: Dong-Bing Zhao, MD, Doctor, Professor, Surgeon, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.

dbzhao2003@sina.com

Telephone: +86-10-87787120

Fax: +86-10-87787120

Abstract

BACKGROUND

The necessity of additional gastrectomy for early gastric cancer (EGC) patients who do not meet curative criteria after endoscopic submucosal dissection (ESD) is controversial.

AIM

To examine the clinicopathologic characteristics of patients who underwent additional laparoscopic gastrectomy after ESD and to determine the appropriate strategy for treating those after noncurative ESD.

METHODS

We retrospectively studied 45 patients with EGC who underwent additional laparoscopic gastrectomy after noncurative ESD from January 2013 to January 2019 at the Cancer Hospital of the Chinese Academy of Medical Sciences. We analyzed the patients' clinicopathological data and identified the predictors of residual cancer (RC) and lymph node metastasis (LNM).

RESULTS

Surgical specimens showed RC in ten (22.2%) patients and LNM in five (11.1%).

Institutional review board

statement: This study was approved by the Institutional Review Board of the National Cancer Center Hospital.

Informed consent statement: The need for informed consent was waived due to the retrospective nature of the study, and the data were anonymously analyzed.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Received: May 5, 2019

Peer-review started: May 6, 2019

First decision: June 10, 2019

Revised: June 28, 2019

Accepted: July 5, 2019

Article in press: July 5, 2019

Published online: August 7, 2019

P-Reviewer: Afzal M, Herbell FAM

S-Editor: Yan JP

L-Editor: Wang TQ

E-Editor: Ma YJ



Multivariate analysis revealed that positive horizontal margin [odds ratio (OR) = 13.393, 95% confidence interval (CI): 1.435-125, $P = 0.023$] and neural invasion (OR = 14.714, 95%CI: 1.087-199, $P = 0.043$) were independent risk factors for RC. Undifferentiated type was an independent risk factor for LNM (OR = 12.000, 95%CI: 1.197-120, $P = 0.035$). Tumors in all patients with LNM showed submucosal invasion more than 500 μm . Postoperative complications after additional laparoscopic gastrectomy occurred in five (11.1%) patients, and no deaths occurred among patients with complications.

CONCLUSION

Gastrectomy is necessary not only for patients who have a positive margin after ESD, but also for cases with neural invasion, undifferentiated type, and submucosal invasion more than 500 μm . Laparoscopic gastrectomy is a safe, minimally invasive, and feasible procedure for additional surgery after noncurative ESD. However, further studies are needed to apply these results to clinical practice.

Key words: Early gastric cancer; Endoscopic submucosal dissection; Laparoscopic gastrectomy; Residual cancer; Lymph node metastasis

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: It is controversial whether additional gastrectomy is necessary for all patients who do not meet the curative criteria after endoscopic submucosal dissection (ESD). Therefore, it would be valuable to determine which factors could increase the risk of residual cancer or lymph node metastasis in patients after noncurative ESD in order to avoid unnecessary surgery. We found that gastrectomy was necessary not only for patients who had a positive margin in ESD, but also for cases with neural invasion, undifferentiated type, and submucosal invasion more than 500 μm . Laparoscopic gastrectomy is a safe, minimally invasive, and feasible procedure for additional surgery after noncurative ESD.

Citation: Tian YT, Ma FH, Wang GQ, Zhang YM, Dou LZ, Xie YB, Zhong YX, Chen YT, Xu Q, Zhao DB. Additional laparoscopic gastrectomy after noncurative endoscopic submucosal dissection for early gastric cancer: A single-center experience. *World J Gastroenterol* 2019; 25(29): 3996-4006

URL: <https://www.wjgnet.com/1007-9327/full/v25/i29/3996.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v25.i29.3996>

INTRODUCTION

Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death in the world^[1]. Early gastric cancer (EGC) is defined as a tumor confined to the mucosa or submucosa, regardless of the regional lymph node metastasis (LNM)^[2]. The detection rates of EGC have been improved with the increase in cancer surveillance and widespread endoscopic examinations^[3]. Endoscopic submucosal dissection (ESD) as a treatment for EGC has been rapidly spreading due to the advantages of this technique including reduced postoperative complications, decreased medical cost, fast recovery, and improved quality of life^[4]. As ESD is now performed more frequently, noncurative ESD is also becoming more and more frequent, thus warranting appropriate treatment^[5].

For patients who have undergone noncurative ESD, some reports^[5-9] recommend additional surgery to prevent residual cancer (RC) or LMN. However, high morbidity, poor quality of life, and medical cost of gastrectomy for these patients cannot be neglected, and it is controversial whether additional gastrectomy is necessary for all patients who do not meet the curative criteria after ESD^[10,11]. Therefore, it would be valuable to determine which factors could increase the risk of RC or LNM in patients after noncurative ESD in EGC patients in order to avoid unnecessary surgery.

Laparoscopic gastrectomy (LG) has been accepted as a standard procedure for the treatment of EGC because it is minimally invasive, results in decreased postoperative pain, and has a shorter recovery time than other procedures^[12,13]. ESD-induced

inflammation causes edema, fibrosis, and intraabdominal adhesions, which might increase the difficulties and the risk of complications during subsequent LG^[3,14]. However, relatively few data are available on the influence of previous ESD on LG^[15-17].

In the present study, we aimed to examine the predictive factors for LNM and RC as well as to explore the appropriate strategy for treating these patients after noncurative ESD. We also aimed to assess the feasibility and safety of LG as additional surgery after ESD.

MATERIALS AND METHODS

In this retrospective cohort study, the clinical data of consecutive EGC patients who underwent additional gastrectomy after ESD at the Cancer Hospital of the Chinese Academy of Medical Sciences, Chinese National Cancer Center between January 2013 and January 2019 were reviewed. The rate of LNM or RC was investigated. The associations between various clinicopathological factors and RC or LNM were examined by univariable and multivariable analyses. This retrospective study was approved by the Institutional Review Board at the Cancer Hospital of the Chinese Academy of Medical Sciences. The need for informed consent was waived due to the retrospective nature of the study, and the data were anonymously analyzed. The datasets in the current study are available from the corresponding author on reasonable request.

Indications and procedures for ESD

Depth of tumor invasion and tumor stage were assessed initially before ESD by endoscopic ultrasonography and contrast-enhanced computed tomography of the abdomen and pelvis. The extended indications for ESD were as follows: (1) Differentiated mucosal cancer without ulceration regardless of lesion size; (2) Differentiated mucosal cancer, with ulceration, < 3 cm in diameter; (3) Differentiated minimally invasive submucosal cancer < 3 cm in diameter; and (4) Undifferentiated mucosal cancer ≤ 2 cm in size.

ESD was performed by one experienced gastrointestinal endoscopist in our hospital. An incision line was made at about 5 mm lateral to the margin of the cancerous lesion using a needle. Hypertonic saline mixed with epinephrine (1:10000) and sodium hyaluronate were injected into the submucosal layer to lift the lesion. A circumferential mucosal incision surrounding the marking dots was performed. The submucosa beneath the target lesion was dissected and the entire lesion was completely removed with a surgical electronic knife.

Histopathological evaluation

After being fixed in 10% formalin, resected specimens were sectioned perpendicularly at 2-mm intervals. The histological evaluation was based on the World Health Organization classification of gastric cancer. Gross types were categorized into elevated, flat, or depressed type. Well or moderately differentiated tubular adenocarcinoma and papillary adenocarcinoma were classified as differentiated adenocarcinoma type, while poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous adenocarcinoma were classified as undifferentiated type. Tumor involvement in the lateral or vertical resection margin, tumor size, lymphovascular invasion, neural invasion, and the depth of tumor invasion were evaluated. The depth of tumor invasion was measured and quantified and was classified as M (mucosal invasion), SM1 (submucosal invasion < 500 μm of the lower margin of the muscularis mucosae), and SM2 (tumor invasion into submucosa > 500 μm from the muscularis mucosa).

Criteria for noncurative resection of ESD

The lesions that were considered not to meet the noncurative criteria for ESD were defined as lesions that met at least one of the following criteria based on histopathologic findings of the ESD specimens: (1) Positive horizontal margin; (2) Positive vertical margin; (3) Presence of lymphovascular involvement; (4) SM2 or deeper invasion; (5) Differentiated mucosal cancer with ulceration and size ≥ 30 mm; (6) Differentiated SM1 cancer ≥ 30 mm; and (7) undifferentiated cancer accompanied by submucosal invasion, size > 20 mm, or ulceration.

Statistical analysis

Univariate analyses by the χ^2 test or Fisher's exact test were performed to explore the clinicopathological differences between the RC and non-RC groups, and between the LNM and non-LNM groups. Furthermore, multivariate logistic regression analysis

was used to identify independent risk factors for RC and LNM, including those factors with $P < 0.3$ in univariate analysis. A P -value < 0.05 was considered significant. All analyses were performed with SPSS for Windows version 22.0.

RESULTS

Demographics and clinicopathological characteristics of the patients

A total of 640 ESDs were performed, and 45 (7.0%) noncurative ESDs were found during the study period. The demographics and clinicopathological characteristics of the patients who received additional gastrectomy because of noncurative ESD are summarized in [Table 1](#). The reasons for additional gastrectomy consisted of positive horizontal margin (7 cases), positive vertical margin (29 cases), SM2 (31 cases), lymphovascular invasion (19 cases), and undifferentiated type (14 cases). And two cases were suspected recurrence on esophagogastroduodenoscopy at the 3-month follow-up after ESD. Of the 45 patients, 34 (75.6%) were male and 11 (24.4%) were female. The mean age was 58.2 ± 9.3 years. The median interval between ESD and additional gastrectomy was 47 ± 26 d. The final depth of tumor invasion was M in 9 patients, SM1 in 5, SM2 in 26, muscularis propria in 2, and subserosa in 3.

Associations between clinicopathological characteristics and RC

RC was found in 10 (22.2%) of the 45 patients. The patients who did and did not have RC were compared in terms of their clinicopathological characteristics, as shown in [Table 2](#). Univariate analyses determined that horizontal margin ($P = 0.034$) and neural invasion ($P = 0.007$) were significant factors for RC. In contrast, tumor location, macroscopic type, tumor size, histological differentiation, Lauren type, vertical margin, depth of invasion, and lymphovascular invasion did not show significant correlations. Multivariate analysis showed that horizontal margin [(odds ratio OR) = 13.393, 95% confidence interval (CI): 1.435-125, $P = 0.023$] and neural invasion (OR = 18.495, 95%CI: 1.585-215, $P = 0.020$) were associated with a higher incidence of RC within specimens after surgery ([Table 3](#)).

Associations between clinicopathological characteristics and LNM

LNM was detected in 5 (11.1%) out of 45 cases. Relationships between clinicopathological characteristics and LNM are summarized in [Table 4](#). Undifferentiated type was the only significant factor for LNM ($P = 0.027$). Macroscopic type and depth of tumor invasion had weak relationships. Multivariate analysis revealed that undifferentiated type (OR = 12.000, 95%CI: 1.197-120, $P = 0.035$) was associated with a higher incidence of LNM within specimens after surgery. All five patients showed tumor depth of more than SM1 in the specimen from the initial endoscopic resection. Of the five patients with LNM, four previously exhibited undifferentiated type post-ESD treatment.

Operative data and postoperative outcomes

Details of the intraoperative course and postoperative course are shown in [Table 5](#). The type of LG was determined based on the tumor location. Proximal gastrectomy was performed in 15 (33.3%) cases and distal gastrectomy in 23 (51.1%). Total gastrectomy was performed in five (11.1%) cases and partial gastrectomy in two (4.4%). The mean number of harvested lymph nodes was 29.7 ± 13.7 . The mean operative time and mean estimated blood loss were 180 ± 47 min and 107 ± 69 mL, respectively. The time to first flatus was 3.4 ± 0.8 d, the time to recommencement of oral intake was 5.3 ± 1.4 d, and the length of hospital stay was 9.9 ± 2.9 d. Postoperative complications occurred five (11.1%) patients. Two patients developed leakage from the anastomotic site, and one each developed wound infection, hemorrhage, and abdominal infection. These complications were conservatively treated and consequently improved. None of these patients died.

DISCUSSION

The rate of RC in our series (22.2%) was similar to those in the previous reports (5.2%-28.6%)^[3,4,18-24]. LNM was detected in 5 (11.1%) out of 45 cases. The majority of these cases harbored neither RC nor LNM, indicating that additional surgery may be unnecessary. Therefore, it is important to identify which patients will benefit the most from additional gastrectomy after noncurative ESD for EGC. However, the studies of predictive factors for RC and LNM in additional surgery gastrectomy specimens after ESD have been very limited. Our study revealed that positive horizontal and neural

Table 1 Demographic characteristics of the patients

Characteristic	All patients (n = 45)	
	Number	Percent
Age (yr)	58.24 ± 9.3	
Gender		
Male	34	75.6
Female	11	24.4
Abdominal operation history		
Yes	8	17.8
No	37	82.2
ASA score		
I-II	34	75.6
III-IV	11	24.4
Comorbidity		
Any comorbidity	15	33.3
Hypertension	10	22.2
Diabetes	5	10.5
Coronary artery disease	2	11.1
Others	4	8.9
Surgical indication		
Vertical margin positive	29	64.4
SM2	31	68.9
Horizontal margin positive	7	15.6
Lymphovascular invasion	19	42.2
Undifferentiated type	14	31.1
Suspected recurrence 3 mo after ESD	2	4.4
Interval (d)	47 ± 26	
RC		
Yes	10	22.2
No	35	77.8
LNM		
Yes	5	11.1
No	40	88.9
Depth of invasion		
T1a	9	20.0
T1b SM1	5	11.1
T1b SM2	26	57.8
T2	2	4.4
T3	3	6.7

RC: Residual cancer; LNM: Lymph node metastasis; ASA: American Society of Anesthesiologists; ESD: Endoscopic submucosal dissection.

invasion were independent risk factors for RC. Undifferentiated type was an independent risk factor for LNM.

Regarding RC, positive vertical margin and positive horizontal margin were independent predictors in some previous studies^[18], while many authors also reported only positive horizontal margin as a risk factor for RC, as found in our study^[4,21,22]. Hyuk *et al* thought that the possibility of the tumor cells in the corresponding area opposite an involved resection margin being completely removed by the cautery effect was much lower in the horizontal rather than in the vertical direction^[4,5]. The feasibility of secondary ESD for local control in positive horizontal margin cases has been reported; however, the management of these patients is debated^[25]. If there is an additional noncurative factor combined with the positive horizontal margin, additional surgery should be considered. Neural invasion is a way of cancer spreading and is related to advanced stage, higher risk of recurrence, and poor long-

Table 2 Characteristics of cases with and without residual cancer, *n* (%)

Characteristic	Residual cancer		P-value
	Yes (<i>n</i> = 10)	No (<i>n</i> = 35)	
Location			1.000
Upper third	4 (23.5)	13 (76.5)	
Middle third	2 (18.2)	9 (81.8)	
Lower third	4 (23.5)	13 (76.5)	
Macroscopic appearance			0.694
Elevated type	1 (25.0)	3 (75.0)	
Surface type	9 (23.1)	30 (76.9)	
Depressed type	0 (0)	2 (100)	
Tumor size			0.720
< 3 cm	5 (19.2)	21 (80.8)	
≥ 3 cm	5 (26.3)	14 (73.7)	
Differentiation			1.000
Differentiated	7 (22.6)	24 (77.4)	
Undifferentiated	3 (21.4)	11 (78.6)	
Lauren type			0.722
Intestinal	4 (18.2)	18 (81.8)	
Diffused/Mixed	6 (26.1)	17 (73.9)	
Depth of invasion			0.469
Mucosal invasion/SM1	2 (14.3)	12 (85.7)	
> SM1 invasion	8 (25.8)	23 (74.2)	
Horizontal margin			0.034
Positive	4 (57.1)	3 (42.9)	
Negative	6 (15.8)	32 (84.2)	
Vertical margin			0.292
Positive	8 (27.6)	21 (72.4)	
Negative	2 (12.5)	14 (87.5)	
Lymphovascular invasion			1.000
Yes	4 (21.1)	15 (78.9)	
No	6 (23.1)	20 (76.9)	
Neural invasion			0.007
Yes	6 (54.5)	5 (45.5)	
No	4 (11.8)	30 (88.2)	

term survival in gastric cancer^[26,27]. In the stomach, the nerve plexuses are concentrated in the Meissner's plexus in the submucosa and Auerbach's plexus between the circular and longitudinal fibers of the muscularis propria^[28]. Thus, neural invasion is observed more frequently in advanced gastric cancer. Interestingly, neural invasion has not been established as a predictor of RC after noncurative ESD, while our study confirmed that neural invasion was an independent risk factor for RC. Although the number of cases was limited, it is a reminder that RC might be detected for those patients with neural invasion and additional gastrectomy may be needed.

In previous studies of patients who underwent additional surgery following noncurative ESD of EGC, the LNM rates ranged from 5.1% to 9.8%^[4,18,19,21,23,24,29,30], which are similar to the present finding of 11.1%. Previous reports have indicated that lymphovascular invasion, SM2 invasion, lesion size > 3 cm, and positive vertical margin were associated with a greater risk of LNM in patients with EGC^[31-33]. Lymphovascular invasion has been proven to be an independent risk factor for LNM in those patients who underwent noncurative ESD^[18,21,34,35]. However, lymphovascular invasion was not correlated with LNM in the present study and two patients without lymphovascular invasion were found to have LNM. Previous studies have demonstrated that the rate of LNM was higher in patients with differentiated EGC with undifferentiated components than in those with EGC without undifferentiated components^[4,36]. Lee *et al*^[37] reported that the rate of LNM increased with the increase in undifferentiated components in differentiated type mucosal cancers. Kim *et al*^[38]

Table 3 Multivariate analysis of the risk factors for residual cancer

Risk factor	OR	95%CI	P-value
Vertical margin positive	0.670	0.065-6.909	0.737
Depth of invasion: > SM1	0.637	0.075-5.423	0.680
Horizontal margin positive	13.393	1.435-125	0.023
Neural invasion positive	18.495	1.585-215	0.020

OR: Odds ratio; CI: Confidence interval.

and Abdelfatah *et al*^[39] demonstrated that undifferentiated histology was an important risk factor for LNM. In the present series, undifferentiated histology was a major risk factor for LNM. SM2 invasion was another factor reported to be associated with a greater risk for LNM in patients with EGC^[30,40]. This was thought to be due to the presence of larger diameter lymphatic vessels in the deeper third of the lamina propria, and the progressive increase in diameter as these vessels go deeper into the submucosal layer, where the lymphatic network is richer^[39]. In our study, tumors in five lymph node-positive patients showed invasion deeper than SM1 in the surgical pathology specimen. Therefore, cases with submucosal invasion deeper than SM1 require additional gastrectomy and lymphadenectomy.

ESD in EGC causes an artificial gastric ulceration, local inflammation, subsequent fibrosis, and even adhesions in the outer gastric wall, which has a negative intraprocedural impact on additional LG in patients who have undergone non-curative ESD^[14]. Previous studies have demonstrated that ESD is not associated with postoperative complications during or after an additional LG in patients who underwent noncurative ESD^[15-17]. Our study found that LG can achieve good short-term surgical outcomes for gastric cancer after noncurative ESD.

This study had several limitations. First, it was a retrospective study conducted in a single center and the sample size was relatively small. Such limitations may lead to issues of selection bias and heterogeneous patient group. Second, we did not report long-term outcomes of patients with noncurative ESD because the mean follow-up period was too short.

In conclusion, gastrectomy is necessary not only for patients who have a positive margin in ESD, but also for cases with neural invasion, undifferentiated type, and submucosal invasion more than 500 μ m due to the risk of RC or LMN. In terms of short-term surgical outcomes, LG is a safe, minimally invasive, and feasible procedure for additional surgery after noncurative ESD. However, further studies are needed to apply these results to clinical practice.

Table 4 Characteristics of patients with and without lymph node metastasis in surgical specimens, *n* (%)

Characteristic	LNM		P-value
	Yes (<i>n</i> = 5)	No (<i>n</i> = 40)	
Location			0.417
Upper third	3 (17.6)	14 (86.7)	
Middle third	0 (0)	11 (100)	
Lower third	2 (11.8)	15 (88.2)	
Macroscopic appearance			0.125
Elevated type	1 (25)	3 (75)	
Surface type	3 (7.7)	36 (92.3)	
Depressed type	1 (50)	1 (50)	
Tumor size			1.000
< 3 cm	3 (11.5)	23 (89.5)	
≥ 3 cm	2 (10.5)	17 (89.5)	
Differentiation			0.027
Differentiated	1 (3.2)	30 (96.8)	
Undifferentiated	4 (28.6)	10 (71.4)	
Lauren type			0.665
Intestinal	3 (13.6)	19 (86.4)	
Diffused/Mixed	2 (8.7)	21 (91.3)	
Depth of invasion			0.305
Mucosal invasion/SM1	0 (0)	14 (100)	
> SM1 invasion	5 (16.1)	26 (83.9)	
Horizontal margin			0.577
Positive	0 (0)	7 (100)	
Negative	5 (13.2)	33 (86.8)	
Vertical margin			1.000
Positive	3 (10.3)	26 (89.7)	
Negative	2 (12.5)	14 (87.5)	
Lymphovascular invasion			0.636
Yes	3 (15.8)	16 (84.2)	
No	2 (7.7)	24 (92.3)	
Neural invasion			1.000
Yes	1 (9.1)	10 (90.9)	
No	4 (11.8)	30 (88.2)	

LNM: Lymph node metastasis.

Table 5 Operative data and postoperative outcomes

Variable	n (%)
Type of gastrectomy	
Proximal	15 (33.3)
Distal	23 (51.1)
Total	5 (11.1)
Partial	2 (4.4)
Retrieved lymph node	29.7 ± 13.7
Complications	
Any	5 (11.1)
Wound infection	1 (2.2)
Postoperative bleeding	1 (2.2)
Anastomotic leakage	2 (4.4)
Abdominal infection	1 (2.2)
30-day mortality	0
Estimated blood loss (mL)	107 ± 69
Operation time (min)	180 ± 47
Time to resume soft diet (d)	5.3 ± 1.4
Time until the first flatus (d)	3.4 ± 0.8
Postoperative hospital stay (d)	9.9 ± 2.9

ARTICLE HIGHLIGHTS

Research background

Endoscopic submucosal dissection (ESD) as a treatment for early gastric cancer (EGC) has been rapidly spreading. As ESD is now performed more frequently, noncurative resection after ESD is also becoming more frequent. It is controversial whether additional gastrectomy is necessary for all patients who do not meet the curative criteria after ESD.

Research motivation

It would be valuable to determine which factors could increase the risk of residual cancer (RC) or lymph node metastasis (LNM) in patients after noncurative ESD of EGC in order to avoid unnecessary surgery.

Research objectives

The objectives of this study were to identify the predictive factors for LNM and RC as well as to explore the appropriate strategy for treating those after non-curative ESD. We also aimed to assess the feasibility and safety of LG as additional surgery after ESD.

Research methods

We analyzed the patients' clinicopathological data and identified the predictors of RC and LNM.

Research results

Surgical specimens showed RC in ten patients and LNM in five. Multivariate analysis revealed that positive horizontal margin and neural invasion were independent risk factors for RC. Undifferentiated type was an independent risk factor for LNM. Tumors in all patients with LNM showed submucosal invasion more than 500 µm. Postoperative complications after additional laparoscopic gastrectomy occurred in five patients, and no deaths occurred among patients with complications.

Research conclusions

Our study revealed that positive horizontal and neural invasion are independent risk factors for RC. Undifferentiated type is an independent risk factor for LNM. Laparoscopic gastrectomy is a safe, minimally invasive, and feasible procedure for additional surgery after noncurative ESD. Gastrectomy is necessary not only for patients who have a positive margin in ESD, but also for cases with neural invasion, undifferentiated type, and submucosal invasion more than 500 µm due to the risk of RC or LNM. Laparoscopic gastrectomy is a safe, minimally invasive, and feasible procedure for additional surgery after noncurative ESD.

Research perspectives

A study of larger sample size is needed. Long-term outcomes of patients with noncurative ESD need to be investigated in a prospective multicenter trial.

REFERENCES

- 1 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: [25651787](#) DOI: [10.3322/caac.21262](#)]
- 2 **Japanese Gastric Cancer Association**. Japanese classification of gastric carcinoma: 3rd English edition. *Gastric Cancer* 2011; **14**: 101-112 [PMID: [21573743](#) DOI: [10.1007/s10120-011-0041-5](#)]
- 3 **Noh GY**, Ku HR, Kim YJ, Park SC, Kim J, Han CJ, Kim YC, Yang KY. Clinical outcomes of early gastric cancer with lymphovascular invasion or positive vertical resection margin after endoscopic submucosal dissection. *Surg Endosc* 2015; **29**: 2583-2589 [PMID: [25480609](#) DOI: [10.1007/s00464-014-3973-0](#)]
- 4 **Toyokawa T**, Ohira M, Tanaka H, Minamino H, Sakurai K, Nagami Y, Kubo N, Yamamoto A, Sano K, Muguruma K, Tominaga K, Nebiki H, Yamashita Y, Arakawa T, Hirakawa K. Optimal management for patients not meeting the inclusion criteria after endoscopic submucosal dissection for gastric cancer. *Surg Endosc* 2016; **30**: 2404-2414 [PMID: [26463497](#) DOI: [10.1007/s00464-015-4491-4](#)]
- 5 **Yoon H**, Kim SG, Choi J, Im JP, Kim JS, Kim WH, Jung HC. Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer. *Surg Endosc* 2013; **27**: 1561-1568 [PMID: [23263643](#) DOI: [10.1007/s00464-012-2627-3](#)]
- 6 **Kusano C**, Iwasaki M, Kaltenbach T, Conlin A, Oda I, Gotoda T. Should elderly patients undergo additional surgery after non-curative endoscopic resection for early gastric cancer? Long-term comparative outcomes. *Am J Gastroenterol* 2011; **106**: 1064-1069 [PMID: [21407189](#) DOI: [10.1038/ajg.2011.49](#)]
- 7 **Lee HJ**, Jang YJ, Kim JH, Park SS, Park SH, Park JJ, Kim SJ, Kim CS, Mok YJ. Clinical Outcomes of Gastrectomy after Incomplete EMR/ESD. *J Gastric Cancer* 2011; **11**: 162-166 [PMID: [22076221](#) DOI: [10.5230/jgc.2011.11.3.162](#)]
- 8 **Eom BW**, Kim YI, Kim KH, Yoon HM, Cho SJ, Lee JY, Kim CG, Kook MC, Kim YW, Nam BH, Ryu KW, Choi IJ. Survival benefit of additional surgery after noncurative endoscopic resection in patients with early gastric cancer. *Gastrointest Endosc* 2017; **85**: 155-163.e3 [PMID: [27460389](#) DOI: [10.1016/j.gie.2016.07.036](#)]
- 9 **Suzuki S**, Gotoda T, Hatta W, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, Hoteya S, Nakagawa M, Hirano M, Esaki M, Matsuda M, Ohnita K, Yamanouchi K, Yoshida M, Dohi O, Takada J, Tanaka K, Yamada S, Tsuji T, Ito H, Hayashi Y, Shimosegawa T. Survival Benefit of Additional Surgery After Non-curative Endoscopic Submucosal Dissection for Early Gastric Cancer: A Propensity Score Matching Analysis. *Ann Surg Oncol* 2017; **24**: 3353-3360 [PMID: [28795364](#) DOI: [10.1245/s10434-017-6039-4](#)]
- 10 **Hatta W**, Gotoda T, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, Hoteya S, Nakagawa M, Hirano M, Esaki M, Matsuda M, Ohnita K, Yamanouchi K, Yoshida M, Dohi O, Takada J, Tanaka K, Yamada S, Tsuji T, Ito H, Hayashi Y, Nakamura T, Nakaya N, Shimosegawa T. Is the eCura system useful for selecting patients who require radical surgery after noncurative endoscopic submucosal dissection for early gastric cancer? A comparative study. *Gastric Cancer* 2018; **21**: 481-489 [PMID: [28983696](#) DOI: [10.1007/s10120-017-0769-7](#)]
- 11 **Heo J**, Jeon SW. The clinical significance and management of noncurative endoscopic resection in early gastric cancer. *Clin Endosc* 2013; **46**: 235-238 [PMID: [23767032](#) DOI: [10.5946/ce.2013.46.3.235](#)]
- 12 **Kim W**, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). *Ann Surg* 2016; **263**: 28-35 [PMID: [26352529](#) DOI: [10.1097/SLA.0000000000001346](#)]
- 13 **Aoyama T**, Sato T, Hayashi T, Yamada T, Cho H, Ogata T, Oba K, Yoshikawa T. Does a laparoscopic approach attenuate the body weight loss and lean body mass loss observed in open distal gastrectomy for gastric cancer? a single-institution exploratory analysis of the JCOG 0912 phase III trial. *Gastric Cancer* 2018; **21**: 345-352 [PMID: [28623524](#) DOI: [10.1007/s10120-017-0735-4](#)]
- 14 **Akagi T**, Shiraishi N, Hiroishi K, Etoh T, Yasuda K, Kitano S. Case series of intra-abdominal adhesions induced by artificial ulceration after endoscopic submucosal dissection before additional laparoscopic gastrectomy. *Gastrointest Endosc* 2010; **72**: 438-443 [PMID: [20541190](#) DOI: [10.1016/j.gie.2010.03.1066](#)]
- 15 **Jiang X**, Hiki N, Yoshida H, Nunobe S, Kumagai K, Sano T, Yamaguchi T. Laparoscopy-assisted gastrectomy in patients with previous endoscopic resection for early gastric cancer. *Br J Surg* 2011; **98**: 385-390 [PMID: [21254013](#) DOI: [10.1002/bjs.7358](#)]
- 16 **Tsujimoto H**, Yaguchi Y, Kumano I, Takahata R, Matsumoto Y, Yoshida K, Horiguchi H, Aosasa S, Ono S, Yamamoto J, Hase K. Laparoscopic gastrectomy after incomplete endoscopic resection for early gastric cancer. *Oncol Rep* 2012; **28**: 2205-2210 [PMID: [22993111](#) DOI: [10.3892/or.2012.2046](#)]
- 17 **Ebihara Y**, Okushiba S, Kurashima Y, Noji T, Nakamura T, Murakami S, Tamoto E, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S. Totally laparoscopic gastrectomy for gastric cancer after endoscopic submucosal dissection: A propensity score matching analysis. *Langenbecks Arch Surg* 2015; **400**: 967-972 [PMID: [26476630](#) DOI: [10.1007/s00423-015-1349-0](#)]
- 18 **Sunagawa H**, Kinoshita T, Kaito A, Shibasaki H, Kaneko K, Ochiai A, Ohtsu A, Nishida T. Additional surgery for non-curative resection after endoscopic submucosal dissection for gastric cancer: A retrospective analysis of 200 cases. *Surg Today* 2017; **47**: 202-209 [PMID: [27194020](#) DOI: [10.1007/s00595-016-1353-1](#)]
- 19 **Ishida R**, Kanaji S, Maehara R, Hasegawa H, Yamamoto M, Matsuda Y, Yamashita K, Matsuda T, Oshikiri T, Sumi Y, Nakamura T, Suzuki S, Kakeji Y. Significance of Additional Gastrectomy Including Endoscopic Submucosal Dissection Scar for Gastric Cancer. *Anticancer Res* 2018; **38**: 5289-5294 [PMID: [30194180](#) DOI: [10.21873/anticancer.12855](#)]
- 20 **Katsube T**, Murayama M, Yamaguchi K, Usuda A, Shimazaki A, Asaka S, Konno S, Miyaki A, Usui T, Yokomizo H, Shiozawa S, Yoshimatsu K, Shimakawa T, Naritaka Y. Additional Surgery After Non-curative Resection of ESD for Early Gastric Cancer. *Anticancer Res* 2015; **35**: 2969-2974 [PMID: [25964583](#)]
- 21 **Ito H**, Inoue H, Ikeda H, Odaka N, Yoshida A, Satodate H, Onimaru M, Takayanagi D, Santi EG, Kudo SE. Surgical outcomes and clinicopathological characteristics of patients who underwent potentially noncurative endoscopic resection for gastric cancer: A report of a single-center experience. *Gastroenterol Res Pract* 2013; **2013**: 427405 [PMID: [23762035](#) DOI: [10.1155/2013/427405](#)]
- 22 **Jung H**, Bae JM, Choi MG, Noh JH, Sohn TS, Kim S. Surgical outcome after incomplete endoscopic submucosal dissection of gastric cancer. *Br J Surg* 2011; **98**: 73-78 [PMID: [21136563](#) DOI: [10.1002/bjs.7274](#)]

- 23 **Kim ER**, Lee H, Min BH, Lee JH, Rhee PL, Kim JJ, Kim KM, Kim S. Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. *Br J Surg* 2015; **102**: 1394-1401 [PMID: [26313295](#) DOI: [10.1002/bjs.9873](#)]
- 24 **Lee JH**, Kim JH, Kim DH, Jeon TY, Kim DH, Kim GH, Park DY. Is Surgical Treatment Necessary after Non-curative Endoscopic Resection for Early Gastric Cancer? *J Gastric Cancer* 2010; **10**: 182-187 [PMID: [22076184](#) DOI: [10.5230/jgc.2010.10.4.182](#)]
- 25 **Bae SY**, Jang TH, Min BH, Lee JH, Rhee PL, Rhee JC, Kim JJ. Early additional endoscopic submucosal dissection in patients with positive lateral resection margins after initial endoscopic submucosal dissection for early gastric cancer. *Gastrointest Endosc* 2012; **75**: 432-436 [PMID: [22248614](#) DOI: [10.1016/j.gie.2011.09.044](#)]
- 26 **De Franco L**, Marrelli D, Voglino C, Vindigni C, Ferrara F, Di Mare G, Iudici L, Marini M, Roviello F. Prognostic Value of Perineural Invasion in Resected Gastric Cancer Patients According to Lauren Histotype. *Pathol Oncol Res* 2018; **24**: 393-400 [PMID: [28555306](#) DOI: [10.1007/s12253-017-0257-8](#)]
- 27 **Liebl F**, Demir IE, Mayer K, Schuster T, D'Haese JG, Becker K, Langer R, Bergmann F, Wang K, Rosenberg R, Novotny AR, Feith M, Reim D, Friess H, Ceyhan GO. The impact of neural invasion severity in gastrointestinal malignancies: A clinicopathological study. *Ann Surg* 2014; **260**: 900-7; discussion 907-8 [PMID: [25379860](#) DOI: [10.1097/SLA.0000000000000968](#)]
- 28 **Kim YB**, Han SU, Lee D. Prominent neural invasion of mucosal gastric cancer into the muscularis propria. *Histopathology* 2017; **71**: 661-662 [PMID: [28524618](#) DOI: [10.1111/his.13259](#)]
- 29 **Nakata B**, Tendo M, Okuyama M, Nakahara K, Ishizu H, Masuda G, Lee T, Hori T, Ohsawa M, Sato H, Ishikawa T. Additional surgical resection after endoscopic mucosal dissection for early gastric cancer: A medium-sized hospital's experience. *Int J Surg* 2016; **36**: 335-341 [PMID: [27871804](#) DOI: [10.1016/j.ijsu.2016.11.084](#)]
- 30 **Yang HJ**, Kim SG, Lim JH, Choi J, Im JP, Kim JS, Kim WH, Jung HC. Predictors of lymph node metastasis in patients with non-curative endoscopic resection of early gastric cancer. *Surg Endosc* 2015; **29**: 1145-1155 [PMID: [25171882](#) DOI: [10.1007/s00464-014-3780-7](#)]
- 31 **Hatta W**, Gotoda T, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, Hoteya S, Nakagawa M, Hirano M, Esaki M, Matsuda M, Ohnita K, Yamanouchi K, Yoshida M, Dohi O, Takada J, Tanaka K, Yamada S, Tsuji T, Ito H, Hayashi Y, Nakaya N, Nakamura T, Shimosegawa T. A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: "eCura system". *Am J Gastroenterol* 2017; **112**: 874-881 [PMID: [28397873](#) DOI: [10.1038/ajg.2017.95](#)]
- 32 **Li H**, Huo ZB, Kong FT, He QQ, Gao YH, Liang WQ, Liu DX. Predictive factors for lymph node metastasis and defining a subgroup treatable for laparoscopic lymph node dissection after endoscopic submucosal dissection in poorly differentiated early gastric cancer. *World J Gastrointest Oncol* 2018; **10**: 360-366 [PMID: [30364712](#) DOI: [10.4251/wjgo.v10.i10.360](#)]
- 33 **Zhao B**, Zhang J, Zhang J, Luo R, Wang Z, Xu H, Huang B. Risk Factors Associated with Lymph Node Metastasis for Early Gastric Cancer Patients Who Underwent Non-curative Endoscopic Resection: A Systematic Review and Meta-analysis. *J Gastrointest Surg* 2019; **23**: 1318-1328 [PMID: [30187319](#) DOI: [10.1007/s11605-018-3924-5](#)]
- 34 **Suzuki H**, Oda I, Abe S, Sekiguchi M, Nonaka S, Yoshinaga S, Saito Y, Fukagawa T, Katai H. Clinical outcomes of early gastric cancer patients after noncurative endoscopic submucosal dissection in a large consecutive patient series. *Gastric Cancer* 2017; **20**: 679-689 [PMID: [27722825](#) DOI: [10.1007/s10120-016-0651-z](#)]
- 35 **Kawata N**, Kakushima N, Takizawa K, Tanaka M, Makuuchi R, Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Sugino T, Kusafuka K, Shimoda T, Nakajima T, Terashima M, Ono H. Risk factors for lymph node metastasis and long-term outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. *Surg Endosc* 2017; **31**: 1607-1616 [PMID: [27495338](#) DOI: [10.1007/s00464-016-5148-7](#)]
- 36 **Takizawa K**, Ono H, Kakushima N, Tanaka M, Hasuike N, Matsubayashi H, Yamaguchi Y, Bando E, Terashima M, Kusafuka K, Nakajima T. Risk of lymph node metastases from intramucosal gastric cancer in relation to histological types: How to manage the mixed histological type for endoscopic submucosal dissection. *Gastric Cancer* 2013; **16**: 531-536 [PMID: [23192620](#) DOI: [10.1007/s10120-012-0220-z](#)]
- 37 **Lee JH**, Choi JJ, Han HS, Kim YW, Ryu KW, Yoon HM, Eom BW, Kim CG, Lee JY, Cho SJ, Kim YI, Nam BH, Kook MC. Risk of lymph node metastasis in differentiated type mucosal early gastric cancer mixed with minor undifferentiated type histology. *Ann Surg Oncol* 2015; **22**: 1813-1819 [PMID: [25344305](#) DOI: [10.1245/s10434-014-4167-7](#)]
- 38 **Kim H**, Kim JH, Park JC, Lee YC, Noh SH, Kim H. Lymphovascular invasion is an important predictor of lymph node metastasis in endoscopically resected early gastric cancers. *Oncol Rep* 2011; **25**: 1589-1595 [PMID: [21455589](#) DOI: [10.3892/or.2011.1242](#)]
- 39 **Abdelfatah MM**, Barakat M, Othman MO, Grimm IS, Uedo N. The incidence of lymph node metastasis in submucosal early gastric cancer according to the expanded criteria: A systematic review. *Surg Endosc* 2019; **33**: 26-32 [PMID: [30298447](#) DOI: [10.1007/s00464-018-6451-2](#)]
- 40 **Miyahara K**, Hatta W, Nakagawa M, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, Hoteya S, Hirano M, Esaki M, Matsuda M, Ohnita K, Shimoda R, Yoshida M, Dohi O, Takada J, Tanaka K, Yamada S, Tsuji T, Ito H, Aoyagi H, Shimosegawa T. The Role of an Undifferentiated Component in Submucosal Invasion and Submucosal Invasion Depth After Endoscopic Submucosal Dissection for Early Gastric Cancer. *Digestion* 2018; **98**: 161-168 [PMID: [29870985](#) DOI: [10.1159/000488529](#)]



Published By Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

